Home » Archives by category » Breaking (Page 2)

FDA approves Gilead’s Yescarta cancer immunotherapy

(Reuters) – A new cancer therapy for a type of lymphoma developed by Kite Pharma, which was recently acquired by Gilead Sciences Inc, won U.S. Food and Drug Administration approval…

Cancer drug prices rising far faster than inflation

(Reuters Health) – The prices of injectable cancer drugs – even older medicines around since the 1990s – are increasing at a rate far higher than inflation, researchers report in…

Trump backs away from Senate deal on stabilizing Obamacare

Trump backs away from Senate deal on stabilizing Obamacare

WASHINGTON (Reuters) – President Donald Trump on Wednesday backed away from a bipartisan deal from two U.S. senators to stabilize Obamacare by restoring subsidies to health insurers, one day after…

McDonald’s South Korea office raided in burger probe: reports

SEOUL (Reuters) – South Korean investigators raided the Seoul office of McDonald’s Corp on Wednesday, following a series of complaints that children fell ill after eating hamburger patties alleged to…

Senate backers of deal to stabilize Obamacare seek to build support

WASHINGTON (Reuters) – Proponents of a bipartisan deal struck by two U.S. senators to stabilize Obamacare were seeking on Wednesday to win Republican support for the measure, which would restore…

McDonald’s South Korea office raided in burger probe: reports

SEOUL (Reuters) – South Korean investigators raided the Seoul office of McDonald’s Corp on Wednesday, following a series of complaints that children fell ill after eating hamburger patties alleged to…

Allergan ruling casts doubt on tribal patent strategy

(Reuters) – A U.S. judge’s ruling on Monday invalidating Allergan Plc’s patents on its blockbuster $1.5 billion dry-eye medicine, Restasis, has cast doubt on the company’s novel strategy to enlist…

Johnson & Johnson wins reversal of $72 million verdict over talc cancer risks

(Reuters) – Johnson & Johnson on Tuesday won the reversal of a $72 million verdict in favor of the family of a woman whose death from ovarian cancer they claimed…

New cancer drugs help Johnson & Johnson top profit estimates

(Reuters) – Johnson & Johnson posted better-than-expected third-quarter earnings, raising its full-year forecast due to growth from new cancer drugs and high-margin treatments picked up in its $30 billion acquisition…

Trump’s drug czar nominee withdraws from consideration

WASHINGTON (Reuters) – President Donald Trump’s pick for U.S. drug czar withdrew on Tuesday after it become public that he spearheaded a bill that undercut the government’s power to crack…